Ceryvyn Therapeutics (ASX: CYV) Jumps 20%: What’s Next for Its LAM Development Program?

Aditi Sarkar

01 September 2026 01:56 PM AEST

Ceryvyn Therapeutics (ASX: CYV) Jumps 20%: What’s Next for Its LAM Development Program?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Ceryvyn Therapeutics is developing a treatment program for lymphangioleiomyomatosis.
The company changed its name and ASX Code to Ceryvyn Therapeutics in July 2026.
CYV reported a cash balance of about AUD 30mn in its latest quarterly update.
The stock traded at AUD 0.012 at the time of writing on 1 September 2026.

Ceryvyn Therapeutics (ASX: CYV) shares rose 20.00% to AUD 0.012 at the time of writing on 1 September 2026. Ceryvyn Therapeutics Limited (ASX: CYV) is continuing its development strategy around lymphangioleiomyomatosis, or LAM, following a change in company name and ASX code during July 2026. The company’s latest disclosures also include quarterly cash-flow information and an update on its development program. The corporate change sits alongside the ongoing work on the company’s lead development program.

LAM Program Remains Central

The company has identified LAM as the key focus of its development work. Earlier in June, Ceryvyn announced reinstatement to trading and an update on the LAM development program, including progression of CYV-101 nebulisation studies. The company also established a Scientific Advisory Board to support the program. These announcements define the development pathway described in the company’s 2026 disclosures.

Financial Position Provides the Current Backdrop

Ceryvyn’s quarterly update reported a cash balance of approximately AUD 30mn at the end of the period and net cash outflow from operations of about AUD 1.1mn. These figures provide the latest disclosed financial backdrop as the company continues its development work. The company’s reporting therefore combines progress on the LAM program with the cash position supporting its ongoing activities.

CYV Share Price Snapshot

At the time of writing on 1 September 2026, CYV shares rose 20.00% to AUD 0.012. The focus remains on the LAM program and the company’s disclosed development activities. Further updates will determine the next milestones in the program.

FAQs

Q: What is Ceryvyn Therapeutics (ASX: CYV) developing?

A: Ceryvyn Therapeutics is developing a treatment program for lymphangioleiomyomatosis.

Q: What is CYV-101?

A: CYV-101 is the company’s development candidate referenced in its LAM program disclosures.

Q: What cash balance did Ceryvyn report?

A: The latest quarterly information cited a cash balance of approximately AUD 30mn.

Q: What was the CYV share price at the time of writing?

A: CYV traded at AUD 0.012 at the time of writing on 1 September 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.